Clinical trials: Osimertinib
Non-small Cell Lung Cancer
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
This multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins…
- Trial name
- NCT05020769
- Testing
- SI-B001, Osimertinib
- Where
- 3 sites in China
- Volunteers
- 14 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Neoplasms, EGFR Gene Mutations
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from…
- Trial name
- LiquidLung-O (NCT02769286)
- Testing
- Osimertinib
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Chonnam National University Hospital
Non Small Cell Lung Cancer
Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)
The purpose of this study is to evaluate the safety and efficacy of neoadjuvant targeted therapy followed by surgery in participants with advanced non-small cell lung cancer.
- Trial name
- NCT05085054
- Testing
- Osimertinib Mesylate
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non-Small Cell Lung Cancer
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the…
- Trial name
- NCT07079475
- Testing
- DZD6008, Sunvozertinib, Osimertinib
- Where
- 14 sites in China
- Volunteers
- 220 people
- Sponsor
- Dizal Pharmaceuticals
Non Small Cell Lung Cancer
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
In this study, we hypothesized that immune engagement by amivantamab will enhance antitumor efficacy by modulating the immune microenvironment in combination with lazertinib in patients with untreated EGFR-mutant NSCLC or with…
- Trial name
- INSTAR (NCT07507188)
- Testing
- Amivantamab SC + Lazertinib PO, Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)
- Volunteers
- 80 people
- Sponsor
- Yonsei University
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-small Cell Lung Cancer
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
This study evaluated the efficacy and safety of gumarontinib combined with third-generation EGFR-TKI in the treatment of locally advanced or metastatic NSCLC with MET amplification after first-line EGFR-TKI failure, without…
- Trial name
- NCT06452433
- Testing
- gumarontinib, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
- Volunteers
- 91 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor…
- Trial name
- CAURAL (NCT02454933)
- Testing
- AZD9291, MEDI4736
- Where
- 13 sites in Canada, South Korea and 1 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers.
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma
- Trial name
- NCT02664935
- Testing
- AZD4547, Vistusertib, Palbociclib
- Where
- 25 sites in United Kingdom
- Volunteers
- 423 people
- Sponsor
- University of Birmingham
NSCLC Patients With Brain Metastasis
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and safety of furmonertinib plus platinum-based doublet chemotherapy (Arm…
- Trial name
- NCT06970639
- Testing
- Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
An External Control Arm Study in Non-Small Cell Lung Cancer
A study to create control arms using current and future information in patients with lung cancer.
- Trial name
- NCT07174388
- Where
- 11 sites in United States
- Volunteers
- 650 people
- Sponsor
- N-Power Medicine
Non-Squamous Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab…
- Trial name
- NCT07005102
- Testing
- Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi)
- Where
- 65 sites in United States, Australia and 11 more
- Volunteers
- 854 people
- Sponsor
- AbbVie
Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
The rationale of the ROSY-T study is to continue to provide study treatment for patients who have participated in a parent study with osimertinib and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-T (NCT05629234)
- Testing
- Osimertinib
- Where
- 27 sites in China, France and 6 more
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Lung Cancer Non-small Cell Stage IV, Brain Metastases
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung…
- Trial name
- NCT03769103
- Testing
- Osimertinib, Stereotactic radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Stage IV Non-small Cell Lung Cancer
SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth…
- Trial name
- NCT05583409
- Testing
- SBRT+Osimertinib, Osimertinib 80 MG
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Li Zhang
Non-small Cell Lung Cancer
Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
The goal of this clinical trial is to assess the feasibility of pharmacokinetically boosting osimertinib using cobicistat in order to improve osimertinib exposure in individual patients with advanced NSCLC (Non-Small Cell Lung…
- Trial name
- OSIBOOST 2 (NCT05748093)
- Testing
- Cobicistat
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht University Medical Center
Lung Cancer, Non-small Cell
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done by PET-CT scan after 6 weeks. In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks.
- Trial name
- NCT02824952
- Testing
- Tagrisso
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Shaare Zedek Medical Center
Third-generation TKI, NSCLC (Advanced Non-small Cell Lung Cancer)
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal…
- Trial name
- NCT06613633
- Testing
- third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
- Where
- 3 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Fudan University
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated…
- Trial name
- UpSwinG (NCT04179890)
- Testing
- Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®)
- Where
- United Kingdom
- Volunteers
- 462 people
- Sponsor
- Boehringer Ingelheim